



STATE OF MARYLAND

DHMH

Maryland Department of Health and Mental Hygiene

Larry Hogan, Governor - Boyd K. Rutherford, Lt. Governor - Dennis R. Schrader, Secretary

MARYLAND MEDICAL ASSISTANCE PROGRAM

Beacon Health Options Transmittal No. 10

Laboratory Transmittal No. 68

Opioid Treatment Providers Transmittal No. 6

January 5, 2017

TO: Beacon Health Options
 Laboratories
 Opioid Treatment Providers

FROM: *Susan J. Tucker*
 Susan J. Tucker, Executive Director
 Office of Health Services

RE: Medicaid Billing for Drug Testing and Screening

NOTE: Please ensure that appropriate staff members in your organization are informed of the contents of this transmittal

Presumptive and definitive drug tests and screening are included as part of the weekly bundled rate Opioid Treatment Programs (OTPs) receive for opioid maintenance treatment (OMT) in accordance with the December 15, 2014 Maryland Medical Assistance Transmittal re: "Medical Billing and Enrollment for Provider Type 32". This directive is in accordance with COMAR 10.09.09.05F, which excludes coverage of laboratory services when the charge is part of a bundled rate. OTPs are responsible for paying laboratories for drug screens and tests for their OMT patients. In order to avoid duplicative billing, laboratories should confirm with the provider whether the ordering provider is an OTP prior to testing.

The bundled weekly rate for OMT services includes reimbursement for point of care drug tests (code 80305) completed in the OTP's office as well tests sent out to laboratories (80306, 80307, and G0480-G0483). This process will be the same under the rebundling initiative that was posted in the Maryland Register on December 09, 2016 and posted on the Department's Behavioral Integration webpage (<http://dhmh.maryland.gov/bhd/Pages/integrationefforts.aspx>). OTPs may engage in contracts with laboratories to reimburse for drug screens and tests beyond point of care drug screens that are completed in the office.

Please see the charts below for a reminder of drug screen and testing codes covered by Maryland Medicaid in calendar year 2015, 2016, and 2017. For questions about this transmittal please contact the Behavioral Health Unit at dhmh.mabehavioralhealth@maryland.gov.

Maryland Medicaid Covered Drug Test and Screen Codes CY 2016 and CY 2017 Crosswalk			
CY 2016 Drug Screen/ Test Codes and Descriptions		CY 2017 Drug Screen/ Test Codes and Descriptions	
Presumptive Drug Testing: Only 80305 (CY 17)/ G0477 (CY 16) may be completed by CLIA waived providers, the other codes must be completed by labs.			
G0477	Drug test(s), presumptive, any number of drug classes; any number of devices or procedure, (eg, immunoassay) capable of being read by direct optical observation only (eg, dipsticks, cups, cards, cartridges), includes sample validation when performed, per date of service	80305	Drug test(s), presumptive, any number of drug classes; any number of devices or procedures, (eg, immunoassay) capable of being read by direct optical observation only (eg, dipsticks, cups, cards, cartridges), includes sample validation when performed, per date of service.
G0478	Drug test(s), presumptive, any number of classes; any number of devices or procedures, (eg, immunoassay) read by instrument-assisted direct optical observation (eg, dipstick, cups, cards, cartridges), includes sample validation when performed, per date of service	80306	Drug test(s), presumptive, any number of drug classes, qualitative, any number of devices or procedures, (eg, immunoassay) read by instrument assisted direct optical observation (eg, dipsticks, cups, cards, cartridges), includes sample validation when performed, per date of service.
G0479	Drug test(s), presumptive, any number of classes; any number of devices or procedures by instrumented chemistry analyzers (eg, immunoassay, enzyme assay, TOF, MALDI, LDTD, DESI, DART, GHPC, GC mass spectrometry), includes sample validation when performed, per date of service	80307	Drug test(s), presumptive, any number of drug classes, qualitative, any number of devices or procedures by instrument chemistry analyzers (eg, utilizing immunoassay [eg, EIA, ELISA, EMIT, FPIA, IA, KIMS, RIA]), chromatography (eg, GC, HPLC), and mass spectrometry etihter with or without chromatography, (eg, DART, DESI, GC-MS, GC-MS/MS, LC-MS, LC-MS/MS, LDTD, MALDI, TOF) includes sample validation when performed, per date of service.
CY 2016 Drug Screen/ Test Codes and Descriptions		CY 2017 Drug Screen/ Test Codes and Descriptions	
Drug Testing: Performed by labs only			
Drug test(s), definitive, utilizing drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to		Drug test(s), definitive, utilizing drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to	

GC/MS (any type, single or tandem) and LC/MS (any type, single or tandem and excluding immunoassays (eg, IA, ELISA, EMIT, FPIA) and enzymatic methods (eg, alcohol dehydrogenase)); qualitative and quantitative, all sources, includes specimen validity testing, per day, for the # of drug class(es) as listed below.		GC/MS (any type, single or tandem) and LC/MS (any type, single or tandem and excluding immunoassays (eg, IA, ELISA, EMIT, FPIA) and enzymatic methods (eg, alcohol dehydrogenase)); qualitative and quantitative, all sources, includes specimen validity testing, per day, for the # of drug class(es) as listed below.	
G0480	1-7 drug class(es), including metabolite(s) if performed.	G0480	No Change
G0481	8-14 drug class(es), including metabolite(s) if performed.	G0481	No Change
G0482	15-21 drug class(es), including metabolite(s) if performed.	G0482	No Change
G0483	22 or more drug class(es), including metabolite(s) if performed.	G0483	No Change

CY 2015 Drug Screen/ Test Codes and Descriptions	
G0434	Drug screen, other than chromatographic; any number of drug classes, by CLIA waved test or moderate complexity test
G0431	Drug Screening, qualitative; multiple classes by high complexity test method
G6040	Alcohol; any specimen except breath
G6042	Amphetamine or methamphetamine
G6043	Barbiturates, not otherwise specified
G6031	Benzodiazepines
80348	Buprenorphine
G6044	Cocaine or metabolite
G6053	Methadone
G6056	Opiate(s), drug and metabolites, each procedure